Pooled analysis of phase III with entacapone in Parkinson's disease

Objectives To investigate efficacy and safety of entacapone across phase III studies in Parkinson's disease (PD) with wearing‐off symptoms. Methods Retrospective, pooled analysis of four phase 3 randomized, double‐blind, placebo‐controlled studies with entacapone. Results 475 of 808 patients wi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Acta neurologica Scandinavica 2014-10, Vol.130 (4), p.239-247
Hauptverfasser:	Kuoppamäki, M., Vahteristo, M., Ellmén, J., Kieburtz, K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antiparkinson Agents - therapeutic use Catechols - therapeutic use Clinical Trials, Phase III as Topic dopamine agonist Dopamine Agonists - therapeutic use Double-Blind Method Drug Therapy, Combination entacapone Female Humans levodopa Levodopa - therapeutic use Male Middle Aged Nausea - chemically induced Nitriles - therapeutic use Parkinson Disease - drug therapy Randomized Controlled Trials as Topic Retrospective Studies selegiline Selegiline - therapeutic use wearing-off
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Objectives To investigate efficacy and safety of entacapone across phase III studies in Parkinson's disease (PD) with wearing‐off symptoms. Methods Retrospective, pooled analysis of four phase 3 randomized, double‐blind, placebo‐controlled studies with entacapone. Results 475 of 808 patients with PD received entacapone and 333 received placebo. Entacapone improved daily OFF‐ and ON‐times (change from baseline) by 0.8 h compared with placebo (P
ISSN:	0001-6314 1600-0404 1600-0404
DOI:	10.1111/ane.12278